How Analysts Rated ANI Pharmaceuticals Inc (NASDAQ:ANIP) Last Week?

July 17, 2017 - By Darrin Black

 How Analysts Rated ANI Pharmaceuticals Inc (NASDAQ:ANIP) Last Week?
Investors sentiment decreased to 1.05 in Q4 2016. Its down 1.28, from 2.33 in 2016Q3. It is negative, as 25 investors sold ANI Pharmaceuticals Inc shares while 41 reduced holdings. 16 funds opened positions while 53 raised stakes. 6.22 million shares or 6.47% more from 5.84 million shares in 2016Q3 were reported.
Dimensional Fund Advsrs Lp holds 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP) or 91,514 shares. Northern Trust reported 103,165 shares. Renaissance Lc owns 232,700 shares. Texas-based Capstone Asset Mngmt has invested 0.01% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Violich Cap Inc stated it has 0.08% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Ativo Capital Management Ltd Liability holds 0.23% or 15,805 shares in its portfolio. Barclays Public reported 0% stake. New York State Teachers Retirement Systems invested in 28,985 shares. Thomson Horstmann & Bryant owns 8,923 shares. Glenmede Trust Na, Pennsylvania-based fund reported 381,031 shares. 1492 Capital Mgmt holds 1.99% or 42,598 shares in its portfolio. Bnp Paribas Arbitrage Sa stated it has 1,348 shares. Pinebridge Investments L P reported 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Blackrock Fund has invested 0.01% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). State Of Alaska Department Of Revenue accumulated 860 shares.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Among 5 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ANI Pharma had 14 analyst reports since July 31, 2015 according to SRatingsIntel. On Thursday, June 23 the stock rating was initiated by Raymond James with “Strong Buy”. The rating was upgraded by Roth Capital on Monday, September 28 to “Buy”. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Buy” rating given on Friday, November 13 by Standpoint Research. The company was maintained on Friday, August 5 by Oppenheimer. The rating was upgraded by TH Capital to “Buy” on Monday, September 28. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Outperform” rating by Oppenheimer on Friday, July 31. The stock has “Hold” rating by Standpoint Research on Tuesday, May 24. Oppenheimer upgraded the stock to “Perform” rating in Tuesday, July 19 report. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Neutral” rating given on Wednesday, February 22 by TH Capital. TheStreet downgraded the stock to “Buy” rating in Wednesday, September 2 report. Below is a list of ANI Pharmaceuticals Inc (NASDAQ:ANIP) latest ratings and price target changes.

22/02/2017 Broker: TH Capital Old Rating: Buy New Rating: Neutral Downgrade

It closed at $47.52 lastly. It is down 0.02% since July 17, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has market cap of $548.28 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 148.37 P/E ratio. The Firm focuses on areas, including controlled substances, anti-cancer , hormones and steroids, and complex formulations.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: which released: “ANI Pharmaceuticals Announces Launch of Authorized Generic of Lithobid …” on December 21, 2016, also with their article: “ANI Pharmaceuticals Announces Launch of Benztropine Mesylate Tablets USP” published on October 25, 2016, published: “ANI Pharmaceuticals Acquires Inderal® XL and InnoPran XL®” on February 24, 2017. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: and their article: “ANI Pharmaceuticals: Coming Back From Oversold Levels” published on March 28, 2017 as well as‘s news article titled: “ANI Pharmaceuticals Revs The Throttle Of Corticotropin Candidate” with publication date: March 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.